- Joined
- Dec 5, 2020
- Messages
- 2,791
Pelacarsen, a powerful therapeutic for lowering Lp(a), is near the end of its Phase III trial to study if it will slow or stop the progression of coronary plaque and heart events. Phase II looked very promising and there is an expectation that once the Phase III results are published it will be approved by the FDA, likely sometime in 2025.
In addition to being causal for heart disease, Lp(a) is also very strongly associated with aortic stenosis and there is another study in the pipeline to study Pelacaren's effectiveness for slowing or stopping the progression of aortic stenosis. They are currently recruiting patients with mild or moderate aortic stenosis for the upcoming Phase II trial.
If anyone one is interested in enrolling or wants more information, see the link below.
https://www.novartis.com/clinicaltrials/study/nct05646381
More info on Lp(a) and its association with heart disease and aortic stenosis.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9820656/
In addition to being causal for heart disease, Lp(a) is also very strongly associated with aortic stenosis and there is another study in the pipeline to study Pelacaren's effectiveness for slowing or stopping the progression of aortic stenosis. They are currently recruiting patients with mild or moderate aortic stenosis for the upcoming Phase II trial.
If anyone one is interested in enrolling or wants more information, see the link below.
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
https://www.novartis.com/clinicaltrials/study/nct05646381
More info on Lp(a) and its association with heart disease and aortic stenosis.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9820656/
